Provided by Tiger Fintech (Singapore) Pte. Ltd.

Enveric Biosciences

1.05
-0.0400-3.67%
Post-market: 1.080.0300+2.86%19:54 EDT
Volume:162.63K
Turnover:171.78K
Market Cap:3.41M
PE:-0.10
High:1.11
Open:1.11
Low:1.02
Close:1.09
52wk High:8.40
52wk Low:1.01
Shares:3.25M
Float Shares:3.22M
Volume Ratio:0.17
T/O Rate:5.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.5042
EPS(LYR):-19.0395
ROE:-261.96%
ROA:-129.73%
PB:1.56
PE(LYR):-0.06

Loading ...

BRIEF-Enveric Biosciences Reports Positive Preclinical Results For Lead Drug Candidate EB-003

Reuters
·
May 28

Enveric Biosciences announces results from EB-003 trial

TIPRANKS
·
May 28

Enveric Biosciences Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Reuters
·
May 28

Enveric Biosciences files new provisional patent application

TIPRANKS
·
May 20

Enveric Biosciences Announces New Provisional Patent Application for Promising Neuroplastogen Candidates Targeting Neurodegenerative Diseases

Reuters
·
May 20

BRIEF-Enveric Biosciences Q1 Net Income USD -2.2 Million

Reuters
·
May 15

Enveric Biosciences Q1 EPS $(1.22) Up From $(9.21) YoY

Benzinga
·
May 15

Enveric Biosciences Secures U.S. Patent for Innovative Mescaline Derivative Compounds in EVM401 Series

Reuters
·
May 15

Press Release: Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Dow Jones
·
May 15

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
Apr 25

Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate

Benzinga
·
Mar 31

Press Release: Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Dow Jones
·
Mar 31

Enveric Biosciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 29

Enveric Biosciences Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
Mar 21

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
Mar 14